Switzerland
  • /
  • Europe
    • FR
    • DE
    • IT
    • ES
    • BE
    • NL
    • LU
    • DK
    • PL
    • UK
  • Switzerland
    • Basel
    • Bern
    • Geneva
    • Lausanne
    • Zürich
  • Schweiz
  • Suisse
  • Alps
  • Business
    • ABB
    • Chubb
    • Glencore
    • Nestlé
    • Novartis
    • Roche
    • UBS
    • Vitol
    • Zurich Insurance
  • People
  • US
  • UK
  • Germany
  • France
  • Africa
  • CH
  • @

Categories

  • ABB
  • Alps
  • Basel
  • Bern
  • Chubb
  • Geneva
  • Glencore
  • Lausanne
  • Nestlé
  • Novartis
  • Roche
  • Switzerland
  • UBS
  • Vitol
  • Zürich
  • Zurich Insurance
Switzerland
  • /
  • Europe
    • FR
    • DE
    • IT
    • ES
    • BE
    • NL
    • LU
    • DK
    • PL
    • UK
  • Switzerland
    • Basel
    • Bern
    • Geneva
    • Lausanne
    • Zürich
  • Schweiz
  • Suisse
  • Alps
  • Business
    • ABB
    • Chubb
    • Glencore
    • Nestlé
    • Novartis
    • Roche
    • UBS
    • Vitol
    • Zurich Insurance
  • People
  • US
  • UK
  • Germany
  • France
  • Africa
  • CH
  • @

Browsing Tag

kidney function

28 posts
RRoche
Positive interim data shows Roche’s sefaxersen significantly reduces proteinuria in people with IgA nephropathy (IgAN)
Read More

Positive interim data shows Roche’s sefaxersen significantly reduces proteinuria in people with IgA nephropathy (IgAN)

  • 2026-10-23
F. Hoffmann-La Roche Ltd In the phase III IMAgINATION study, sefaxersen demonstrated statistically significant and clinically meaningful reductions…
RRoche
Ionis announces positive interim data from partner Roche’s Phase 3 IMAgINATION study in IgA nephropathy (IgAN)
Read More

Ionis announces positive interim data from partner Roche’s Phase 3 IMAgINATION study in IgA nephropathy (IgAN)

  • 2026-10-17
– Sefaxersen demonstrated statistically significant and clinically meaningful reductions in proteinuria versus placebo at 37 weeks, showing best-in-class…
RRoche
Positive interim data shows Roche’s sefaxersen significantly reduces proteinuria in people with IgA nephropathy (IgAN)
Read More

Positive interim data shows Roche’s sefaxersen significantly reduces proteinuria in people with IgA nephropathy (IgAN)

  • 2026-10-01
F. Hoffmann-La Roche Ltd In the phase III IMAgINATION study, sefaxersen demonstrated statistically significant and clinically meaningful reductions…
RRoche
Roche Drops as Phase 3 Kidney Signal Needs Two-Year Proof
Read More

Roche Drops as Phase 3 Kidney Signal Needs Two-Year Proof

  • 2026-09-30
This article first appeared on GuruFocus. Roche Holding (RHHBY), the pharmaceuticals and diagnostics group, reported that its experimental…
RRoche
Roche, Ionis RNA drug scores in kidney disease study
Read More

Roche, Ionis RNA drug scores in kidney disease study

  • 2026-09-24
This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free…
RRoche
Roche Drops as Phase 3 Kidney Signal Needs Two-Year Proof
Read More

Roche Drops as Phase 3 Kidney Signal Needs Two-Year Proof

  • 2026-09-24
This article first appeared on GuruFocus. Roche Holding (RHHBY), the pharmaceuticals and diagnostics group, reported that its experimental…
RRoche
Positive interim data shows Roche’s sefaxersen significantly reduces proteinuria in people with IgA nephropathy (IgAN)
Read More

Positive interim data shows Roche’s sefaxersen significantly reduces proteinuria in people with IgA nephropathy (IgAN)

  • 2026-09-23
F. Hoffmann-La Roche Ltd In the phase III IMAgINATION study, sefaxersen demonstrated statistically significant and clinically meaningful reductions…
RRoche
FDA grants Priority Review to Roche’s Gazyva/Gazyvaro for adults with primary membranous nephropathy
Read More

FDA grants Priority Review to Roche’s Gazyva/Gazyvaro for adults with primary membranous nephropathy

  • 2026-07-22
F. Hoffmann-La Roche Ltd Priority Review decision is based on phase III MAJESTY results, where Gazyva/Gazyvaro achieved significantly…
NNovartis
Can Novartis' Fabhalta Strengthen Its Nephrology Franchise?
Read More

Can Novartis’ Fabhalta Strengthen Its Nephrology Franchise?

  • 2026-07-17
Novartis NVS announced that the FDA has granted traditional approval to Fabhalta (iptacopan) for slowing kidney function decline…
NNovartis
Novartis (SWX:NOVN) Wins Full FDA Nod For Fabhalta And Wider EU Itvisma Use
Read More

Novartis (SWX:NOVN) Wins Full FDA Nod For Fabhalta And Wider EU Itvisma Use

  • 2026-07-17
Make better investment decisions with Simply Wall St’s easy, visual tools that give you a competitive edge. Novartis…
NNovartis
FDA grants traditional approval to Novartis’ Fabhalta for IgAN
Read More

FDA grants traditional approval to Novartis’ Fabhalta for IgAN

  • 2026-07-17
The US Food and Drug Administration (FDA) has issued traditional approval to Novartis for Fabhalta (iptacopan), to slow…
NNovartis
Novartis Fabhalta® (iptacopan) receives FDA traditional approval as first and only complement inhibitor to significantly slow kidney function decline in primary IgAN
Read More

Novartis Fabhalta® (iptacopan) receives FDA traditional approval as first and only complement inhibitor to significantly slow kidney function decline in primary IgAN

  • 2026-07-17
Novartis Pharma AG Fabhalta slowed eGFR decline by 48% vs placebo over two years, demonstrating kidney function preservation1 …
Switzerland
www.europesays.com